Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

302.96 +0.22 (+0.07%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗

July 10, 2025

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.

Via Benzinga

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗

July 09, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings ↗

April 17, 2025

Via Benzinga

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated ↗

April 17, 2025

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Via Stocktwits

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews ↗

December 11, 2024

Via Benzinga

A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals ↗

November 08, 2024

Via Benzinga

Dow Falls Over 1%; US Initial Jobless Claims Decline ↗

April 17, 2025

Via Benzinga

Topics Stocks

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity ↗

April 17, 2025

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Via Benzinga

Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy ↗

April 10, 2025

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Via Benzinga

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 10, 2025

Via Benzinga

Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts ↗

October 21, 2024

Via Benzinga

The Latest Analyst Ratings For Ligand Pharmaceuticals ↗

October 03, 2024

Via Benzinga

Looking Into Ligand Pharmaceuticals's Recent Short Interest ↗

August 16, 2024

Via Benzinga

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

February 13, 2025

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 06, 2025

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

December 10, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗

December 09, 2024

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Via Investor's Business Daily

Ligand to Present at Stifel 2024 Healthcare Conference

November 14, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

November 07, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

November 01, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

October 23, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know ↗

October 21, 2024

Via Benzinga

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

October 17, 2024

Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment...

From Palvella Therapeutics

Via GlobeNewswire

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

September 06, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

August 20, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.